W. Callicutt Jack's most recent trade in Galectin Therapeutics Inc was a trade of 28,120 Stock option (right to buy) done . Disclosure was reported to the exchange on Nov. 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 28,120 | 0 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.22 per share. | 17 Nov 2025 | 28,100 | 7,614 (0%) | 0% | 6.2 | 174,866 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 17 Nov 2025 | 28,100 | 35,714 (0%) | 0% | 2.0 | 55,638 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 19,701 | 18,190 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 17 Nov 2025 | 19,701 | 7,614 (0%) | 0% | 6.0 | 118,831 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 17 Nov 2025 | 19,701 | 27,315 (0%) | 0% | 1.1 | 21,868 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.22 per share. | 17 Nov 2025 | 18,210 | 7,614 (0%) | 0% | 6.2 | 113,321 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 17 Nov 2025 | 18,210 | 25,824 (0%) | 0% | 1.1 | 20,213 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 18,190 | 0 | - | - | Common stock (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 17 Nov 2025 | 9,586 | 17,200 (0%) | 0% | 2.0 | 18,980 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 9,586 | 28,120 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 17 Nov 2025 | 9,586 | 7,614 (0%) | 0% | 6.0 | 57,820 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 2,323 | 48,750 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 17 Nov 2025 | 2,323 | 7,614 (0%) | 0% | 6.0 | 14,012 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 17 Nov 2025 | 2,323 | 9,937 (0%) | 0% | 1.2 | 2,857 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.02 per share. | 10 Nov 2025 | 1,880 | 7,614 (0%) | 0% | 6.0 | 11,321 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 10 Nov 2025 | 1,880 | 9,694 (0%) | 0% | 2.0 | 3,722 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 1,880 | 37,706 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 10 Nov 2025 | 1,736 | 9,350 (0%) | 0% | 1.2 | 2,135 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 1,736 | 51,073 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 10 Nov 2025 | 1,736 | 7,614 (0%) | 0% | 6.0 | 10,468 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 10 Nov 2025 | 1,675 | 7,614 (0%) | 0% | 6.0 | 10,095 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 10 Nov 2025 | 1,675 | 9,289 (0%) | 0% | 1.1 | 1,859 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 1,675 | 37,891 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.72 per share. | 05 Nov 2025 | 200 | 7,814 (0%) | 0% | 1.7 | 344 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 05 Nov 2025 | 200 | 7,614 (0%) | 0% | 6 | 1,200 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 05 Nov 2025 | 200 | 7,814 (0%) | 0% | 1.1 | 222 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 05 Nov 2025 | 200 | 7,614 (0%) | 0% | 6 | 1,200 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 05 Nov 2025 | 200 | 7,814 (0%) | 0% | 2.0 | 396 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2025 | 200 | 52,809 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2025 | 200 | 39,566 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2025 | 200 | 39,586 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 05 Nov 2025 | 200 | 7,614 (0%) | 0% | 6 | 1,200 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 10,741 | 53,009 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.07 per share. | 03 Nov 2025 | 10,741 | 7,614 (0%) | 0% | 6.1 | 65,198 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.72 per share. | 03 Nov 2025 | 10,741 | 18,355 (0%) | 0% | 1.7 | 18,475 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 8,974 | 39,766 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.07 per share. | 03 Nov 2025 | 8,974 | 7,614 (0%) | 0% | 6.1 | 54,472 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 03 Nov 2025 | 8,974 | 16,588 (0%) | 0% | 1.1 | 9,961 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 8,914 | 39,786 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.07 per share. | 03 Nov 2025 | 8,914 | 7,614 (0%) | 0% | 6.1 | 54,108 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 03 Nov 2025 | 8,914 | 16,528 (0%) | 0% | 2.0 | 17,650 | Common stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.01 per share. | 03 Nov 2025 | 1,300 | 7,614 (0%) | 0% | 6.0 | 7,813 | Common Stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 03 Nov 2025 | 1,300 | 8,914 (0%) | 0% | 2.0 | 2,574 | Common Stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 1,300 | 48,700 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 03 Nov 2025 | 1,260 | 8,874 (0%) | 0% | 1.1 | 1,399 | Common Stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 1,260 | 48,740 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.01 per share. | 03 Nov 2025 | 1,260 | 7,614 (0%) | 0% | 6.0 | 7,573 | Common Stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 1,250 | 63,750 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.01 per share. | 03 Nov 2025 | 1,250 | 7,614 (0%) | 0% | 6.0 | 7,513 | Commno stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.72 per share. | 03 Nov 2025 | 1,250 | 8,864 (0%) | 0% | 1.7 | 2,150 | Common Stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.37 per share. | 12 Sep 2025 | 8,706 | 16,320 (0%) | 0% | 1.4 | 11,927 | Common Stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2025 | 8,706 | 0 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.44 per share. | 12 Sep 2025 | 8,706 | 7,614 (0%) | 0% | 6.4 | 56,054 | Common Stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Restricted Stock Unit | |
| Galectin Therapeutics Inc | W. Callicutt Jack | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 40,000 | 47,614 (0%) | 0% | 0 | Common Stock | |
| Galectin Therapeutics Inc | W. Jack Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.89 per share. | 23 Dec 2024 | 40,000 | 7,614 (0%) | 0% | 0.9 | 35,492 | Common Stock |
| Galectin Therapeutics Inc | Callicutt W. Jack | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 40,000 | 0 | - | - | Restricted Stock Units | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | W. Callicutt Jack | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 40,000 | 40,000 | - | - | Restricted Stock Unit | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.32 per share. | 17 Nov 2022 | 4,000 | 7,614 (0%) | 0% | 1.3 | 5,280 | Common Stock |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 100,000 | 100,000 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 50,000 | 50,000 | - | - | Stock option (right to buy) |